Evidence map›Paper›PMID 39972382›Full record

ArticleBMC medical informatics and decision making2025

Modeling-based design of adaptive control strategy for the effective preparation of 'Disease X'.

Hao Wang, Weike Zhou, Xia Wang, Yanni Xiao, Sanyi Tang, Biao Tang

Abstract read
In one paragraph

Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hao WangSchool of Mathematics and Statistics, Shaanxi Normal University, Xi'an, PR, 710062, China.
Weike ZhouSchool of Mathematics, Northwest University, Xi'an, PR, 710127, China.
Xia WangSchool of Mathematics and Statistics, Shaanxi Normal University, Xi'an, PR, 710062, China.
Yanni XiaoSchool of Mathematics and Statistics, Xi'an Jiaotong University, Xi'an, PR, 710049, China.
Sanyi TangShanxi Key Laboratory for Mathematical Technology in Complex Systems, Shanxi University, Taiyuan, P.R., 030006, China. sytang@sxu.edu.cn.
Biao TangSchool of Mathematics and Statistics, Xi'an Jiaotong University, Xi'an, PR, 710049, China. biaotang@xjtu.edu.cn.

Funding

National Natural Science Foundation of China 12001349National Natural Science Foundation of China 12031010National Natural Science Foundation of China 12371502
6 · The paper itself

Abstract

This study aims at exploring a general and adaptive control strategy to confront the rapid evolution of an emerging infectious disease ('Disease X'), drawing lessons from the management of COVID-19 in China. We employ a dynamic model incorporating age structures and vaccination statuses, which is calibrated using epidemic data. We therefore estimate the cumulative infection rate (CIR) during the first epidemic wave of Omicron variant after China relaxed its zero-COVID policy to be 82.9% (95% CI: 82.3%, 83.5%), with a case fatality rate (CFR) of 0.25% (95% CI: 0.248%, 0.253%). We further show that if the zero-COVID policy had been eased in January 2022, the CIR and CFR would have decreased to 81.64% and 0.205%, respectively, due to a higher level of immunity from vaccination. However, if we ease the zero-COVID policy during the circulation of Delta variant from June 2021, the CIR would decrease to 74.06% while the CFR would significantly increase to 1.065%. Therefore, in the face of a 'Disease X', the adaptive strategies should be guided by multiple factors, the 'zero-COVID-like' policy could be a feasible and effective way for the control of a variant with relative low transmissibility. However, we should ease the strategy as the virus matures into a new variant with much higher transmissibility, particularly when the population is at a high level of immunity.

Indexed as

Communicable Disease ControlCommunicable Diseases, EmergingCOVID-19AdultChinaHumansSARS-CoV-2Adaptive controlAge structureDisease XImmune attenuationZero-COVID policy

Identifiers

PMID39972382
PMCPMC11841272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.